Biogen, AbbVie Get FDA Approval for Monthly MS Drug

The FDA May 27 approved Zinbryta (daclizumab) for treating adults with relapsing forms of multiple sclerosis (MS).

Zinbryta is a long-acting injection that is self-administered by the patient monthly, the Food and Drug Administration said. The agency said Zinbryta should generally be used only in patients who have had an inadequate response to at least two MS drugs because Zinbryta has serious safety risks, including liver injury and immune conditions.

Biogen Inc. and AbbVie are co-promoting Zinbryta in the U.S.

“Zinbryta provides an additional choice to patients who may require a new option for treatment,” said Billy Dunn, director of ...